Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive 1

Interventions

Magnetic Resonance Spectroscopy 6Temozolomide 4Radiotherapy 3Cyclophosphamide 3Carmustine 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3sargramostim 2aldesleukin 2Thalidomide 2Paclitaxel 2Gadolinium DTPA 2Filgrastim 2Donepezil 2Biopsy 2temsirolimus 1surufatinib 1plerixafor 1omburtamab I-131 1ganitumab 1gallium Ga 68 dotatate 1gadobutrol 1gadobenic acid 1entinostat 1cixutumumab 1carboxyamido-triazole 1azurin (50-77) 1antineoplaston AS 2-1 1antineoplaston A10 1adavosertib 1Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × PM 00104 × Sarcoma × Clear all
NCT01222767 2021-10-29

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

PharmaMar

Phase 2 Completed
17 enrolled 20 charts
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡